2TK Stock Chart & Stats
€2.88
€0.04(1.27%)
At close: 4:00 PM EDT
€2.88
€0.04(1.27%)
Day’s Range― - ―
52-Week Range€1.17 - €3.70
Previous CloseN/A
Volume0.00
Average Volume (3M)86.00
Market Cap
€164.15M
Enterprise Value€398.44M
Total Cash (Recent Filing)€88.76M
Total Debt (Recent Filing)€467.00K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 18, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding81,261,154
10 Day Avg. Volume0
30 Day Avg. Volume86
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.47Price Target Upside194.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces solvency pressure and interest obligations while preserving flexibility to direct capital toward clinical development. Although the company remains loss-making, its limited leverage avoids adding substantial fixed repayment burdens during a period when external funding may be needed.
Targeted Immunology ApproachA targeted immune-modulation strategy could offer a differentiated therapeutic profile if clinical results support the intended benefits. Addressing graft rejection while potentially reducing broad immunosuppression gives the lead program a clear clinical objective in transplantation and autoimmune care.
Multiple Potential IndicationsApplying the platform and lead candidate across transplantation and autoimmune diseases creates multiple potential development and commercialization paths. This indication breadth may improve strategic flexibility and provide more than one route to future product value if efficacy and safety are demonstrated.
Bears Say
No Product RevenueThe absence of product revenue means operations are not self-funded and depend on continued access to external capital. Until a therapy is approved and commercialized, development spending will continue without an established recurring revenue base to absorb research and corporate costs.
Deepening LossesLarge and recently worsening losses show that the business remains far from breakeven and that operating scale has not yet translated into earnings. Sustained negative EBIT reduces financial resilience and increases the amount of capital required to advance the pipeline toward commercialization.
Persistent Cash BurnOngoing operating and free-cash-flow deficits consume the resources needed to fund clinical programs, while declining equity is consistent with cumulative losses. If this burn persists, additional financing may be required, potentially constraining development plans or diluting existing ownership.
Eledon Pharmaceuticals News
2TK FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was €1.17 and its highest was €3.70 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is €164.15M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 32 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported -€0.24 earnings per share for the quarter, missing the consensus estimate of -€0.141 by -€0.1.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.17.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 81,261,154 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -€0.24 in its last earnings report, missing expectations of -€0.141. Following the earnings report the stock price went down -1.887%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:2TK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.47 (194.13% Upside)
€8.47 (194.13% Upside)
Blogger Sentiment
Bullish
DE:2TK Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.26%
12-Months-Change
Fundamentals
Return on Equity
-136.45%
Trailing 12-Months
Asset Growth
-12.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
2TK Stock 12 Month Forecast
Average Price Target
€8.47
▲(194.13% Upside)
Technical Analysis
MacroGenics
―
Fate Therapeutics
―
ProQR
―
Bicycle Therapeutics
―
SAB Biotherapeutics
―